Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine.
Reilly
Raymond M
RM
University of Toronto, Toronto, Ontario, Canada. raymond.reilly@utoronto.ca
D000906:Antibodies / Q000008:administration & dosage* / Q000378:metabolism; D002463:Cell Membrane Permeability; D002614:Chelating Agents / Q000737:chemistry; D016503:Drug Delivery Systems; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry; D006801:Humans; D007205:Indium Radioisotopes / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D016393:Lymphoma, B-Cell / Q000378:metabolism; D037742:Nanotubes, Carbon / Q000009:adverse effects; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics
D000906:Antibodies; D002614:Chelating Agents; D006573:Heterocyclic Compounds, 1-Ring; D007205:Indium Radioisotopes; D037742:Nanotubes, Carbon; D019275:Radiopharmaceuticals; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid